- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
[VIRTUAL] CORTICOSTEROID TAPERING AND DISCONTINUATION IN A PHASE 2 STUDY OF RILONACEPT IN RECURRENT PERICARDITIS (eAbstract Virtual Hall) - Dec 22, 2019 - Abstract #ACC2020ACC_5516; In this Phase 2 study, rilonacept treatment reduced pain and CRP and enabled tapering and discontinuation of CS in RP of idiopathic or PPS etiology without inducing disease recurrence. This CS-sparing effect of rilonacept has the potential to decrease or even obviate CS use in RP and could represent an important therapeutic opportunity for targeted treatment of this serious and debilitating disease.
- |||||||||| Arcalyst (rilonacept) / Regeneron
NOVEL NOD2 MUTATION CAUSING NOD2 ASSOCIATED AUTOINFLAMMATORY DISEASE (NAID) (Monitor 5) - Nov 9, 2019 - Abstract #ACAAI2019ACAAI_776; She is currently on treatment with Rilonacept, with symptom control...Loss of structure or function variants of NOD2 are known to be pathogenic, causing several diseases. This case reinforces the need to functionally evaluate all mutations found in patients with unusual clinical pictures.
- |||||||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Biomarker, PK/PD data, Journal: Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis. (Pubmed Central) - Sep 6, 2019 Our results revealed golimumab- and mavrilimumab-specific pharmacodynamic biomarkers, and demonstrated differential biomarker-treatment relationships in anti-TNF-IR and DMARD-IR patients, respectively. Early IL-6 change after anti-TNF antibody treatment may be a potential predictive biomarker for selection of different treatment regimens in anti-TNF-IR patients.
- |||||||||| Ilaris (canakinumab) / Novartis
Clinical, Journal: Canakinumab treatment in renal transplant recipients with familial Mediterranean fever. (Pubmed Central) - Aug 15, 2019 We report here the efficacy and safety of canakinumab in three renal transplant recipients who achieved a complete clinical response with elimination of attacks and normalization of serum C-reactive protein (CRP) levels without significant side effects. This highlights the advantage of use of this drug in this setting, which has a better tolerability compared to anakinra.
- |||||||||| Kineret (anakinra) / SOBI, Affibody, Arcalyst (rilonacept) / Regeneron, Ilaris (canakinumab) / Novartis
Journal: The Future of IL-1 Targeting in Kidney Disease. (Pubmed Central) - May 17, 2019 Additionally, experimental evidence suggests a role of IL-1 in kidney disease and hypertension and targeting IL-1 showed promising results in high cardiovascular risk patients, hemodialysis and renal transplantation patients. We now summarize knowledge on the potential role of IL-1 targeting in patients with kidney disease.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion: Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) - Jul 17, 2018 P2, N=20, Completed, Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Enrollment closed: Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) - Dec 15, 2017 P2, N=20, Active, not recruiting, Phase classification: P=N/A --> P2 Recruiting --> Active, not recruiting
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Biomarker, Trial completion: IL1-TRAP, Rilonacept, in Systemic Sclerosis (clinicaltrials.gov) - Dec 5, 2017 P1/2, N=21, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Enrollment open, Trial initiation date, Trial primary completion date: Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss (clinicaltrials.gov) - Sep 13, 2017 P, N=10, Recruiting, Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2017 | Trial primary completion date: Jun 2017 --> Mar 2018
- |||||||||| mavrilimumab (KPL-301) / Kiniksa
Trial initiation date, Trial termination: A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 1, 2017 P2, N=409, Terminated, Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2017 | Trial primary completion date: Jun 2017 --> Mar 2018 Initiation date: Dec 2002 --> Jan 2013 | Completed --> Terminated; The study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Biomarker, Enrollment closed, Enrollment change: IL1-TRAP, Rilonacept, in Systemic Sclerosis (clinicaltrials.gov) - Mar 30, 2017 P1/2, N=19, Active, not recruiting, Initiation date: Dec 2002 --> Jan 2013 | Completed --> Terminated; The study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations. Recruiting --> Active, not recruiting | N=40 --> 19
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial primary completion date: Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) - Jan 6, 2017 P2, N=20, Recruiting, Recruiting --> Active, not recruiting | N=40 --> 19 Trial primary completion date: Feb 2017 --> Dec 2017
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial primary completion date: Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) - Jan 29, 2016 P2, N=20, Recruiting, Active, not recruiting --> Completed | Initiation date: Aug 2012 --> Dec 2002 Trial primary completion date: Apr 2016 --> Feb 2017
|